<DOC>
	<DOCNO>NCT00751530</DOCNO>
	<brief_summary>This retrospective chart review participant raltegravir expanded access program compare virologic response regimens contain protease inhibitor antiretroviral background regimen regimens contain protease inhibitor background regimen .</brief_summary>
	<brief_title>BRAVO : Background Regimen Raltegravir Virologic Outcome</brief_title>
	<detailed_description>EAP chart patient study site meet inclusion criterion review data abstract . A comparison response treatment viral load measurement raltegravir compare patient whose regimen contain protease inhibitor ( PI ) contain PI . Other endpoint also assess include percent patient viral load le 400 copies/ml , less 50 copies/ ml , CD4 cell change , consequence failure raltegravir use predictive parameter GSS PSS .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients previously enrol MK 0518 EAP eligible Patients enrol MK 0518 EAP ( Raltegravir protocol ) meet specific EAP protocol entry criterion eligible : Age &gt; = 16 year Limited treatment option due resistance intolerance multiple antiretroviral regimen , document resistance least one drug 3 class oral ARTs ( NRTI , NNRTI , PI ) genotype phenotype testing , intolerance define clinically significant adverse event opinion clinician provide contraindication use drug class iii . Patient achieve virologic suppression ART regimen prior receipt raltegravir iv . Patient clinically stable time initiation raltegravir , eg . clinical status chronic medication ( except ARTs ) unchanged &gt; = 2 week prior raltegravir receipt . Patient receive raltegravir least 8 week Baseline week 8 later HIV viral load do available review Resistance test ( either genotypic phenotypic test ) available prior receipt raltegravir Patient receive approve raltegravir dose 400 mg BID least 8 week . Patient chart available review .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>raltegravir</keyword>
	<keyword>BRAVO</keyword>
	<keyword>protease inhibitor</keyword>
	<keyword>treatment Experienced</keyword>
</DOC>